Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Entrepreneurship Beckons As Eisai India Chief Departs

Thu, 11/21/2019 - 8:06pm

Eisai Pharmaceuticals India's managing director has left the company and plans to start his own venture.

      Related Stories 

Multiple Alliances Expand Brii’s Commitment To Anti-Infectives

Thu, 11/21/2019 - 2:19pm

China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an...

      Related Stories 

With Celgene Acquisition Closed, Bristol Faces Major Milestones

Thu, 11/21/2019 - 2:11pm

Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will...

      Related Stories 

EU Approvals: J&J's Darzalex Steps Ahead With New Indication

Thu, 11/21/2019 - 7:29am

The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two...

      Related Stories 

New Indication For Lenvima In India Spawns Opportunities For Many?

Wed, 11/20/2019 - 10:31pm

Eisai’s lenvatinib is endorsed by an expert panel in India in combination with everolimus, for which multiple generic brands are...

      Related Stories 

Advent Gains High-Potential ART Business Through Bharat Buy

Wed, 11/20/2019 - 9:38pm

With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The...

      Related Stories 

For An Ultra-High-Priced Drug, Alnylam Brings A New Idea

Wed, 11/20/2019 - 1:01pm

The company will launch Givlaari with a novel prevalence-based adjustment feature for payers, which will trigger higher rebates if the...

      Related Stories 

Alnylam Wins FDA Approval For Givlaari, Its Second RNAi Drug

Wed, 11/20/2019 - 11:49am

Givosiran was approved by the US FDA for the treatment of acute hepatic porphyria, a rare generic blood disorder, nearly...

      Related Stories 

Real-World Evidence: Sanofi Push Driven By Aetion Deal

Wed, 11/20/2019 - 7:04am

Sanofi and US start-up Aetion are to collaborate on integrating their real-world evidence and analytics platforms to improve the clinical...

      Related Stories 

The Medicines Company Rises On Novartis Takeover Rumors

Wed, 11/20/2019 - 6:43am

It's been a good week for the US company with its PCSK9 gene-silencing drug impressing at the American Heart Association...

      Related Stories 

Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales

Tue, 11/19/2019 - 1:33pm

The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through...

      Related Stories 

Myovant Ready To File Relugolix For Prostate Cancer

Tue, 11/19/2019 - 1:06pm

Secondary endpoint assessing cardiovascular risk may offer important differentiation from AbbVie’s Lupron. Myovant accelerated the prostate cancer filing soon after...

      Related Stories 

The Healthcare World According To Andrew Witty

Tue, 11/19/2019 - 7:37am

The former GlaxoSmithKline CEO has given his views on the prospects for healthcare systems, saying that intelligently applying digital technologies...

      Related Stories 

Novo Nordisk Enters Its First Strategic RNAi Pact

Tue, 11/19/2019 - 7:37am

Novo Nordisk’s head of global drug discovery tells Scrip he hopes the strategic collaboration with Dicerna Pharmaceuticals will generate clinical...

      Related Stories 

Karuna Upbeat On New Antipsychotic Mechanism Data

Tue, 11/19/2019 - 6:43am

Karuna Therapeutics’ top-line Phase II data for a combination of a centrally acting muscarinic agonist, xanomeline, and a peripherally acting...

      Related Stories 

Pages